Status:
Ready to upload
Record number:
1893
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Comprehensive review article of urologic malignancy in kidney transplantation. Both renal cell carcinoma (RCC) and urothelial carcinoma (RC) are covered. Lifetime risk of renal cancer is 1.62% in US general population. Compared with the general population, kidney transplant recipients have a 5-7 fold increased risk of renal cancers with RCC accounting for 4.6% of post renal transplantation malignancies. 90% RCC develop in native kidneys, as opposed to the allograft.
Time to detection:
5% of patients on waitlist have RCC at time of transplantation. Use of kidney with small RCC as donor source occurs (with RCC resection pre-transplantation) and the available literature supports this practice due to shortage of allografts for this population. Time to detection N/A for this review article.
Alerting signals, symptoms, evidence of occurrence:
N/A
Demonstration of imputability or root cause:
N/A
Imputability grade:
Not Assessable
Groups audience:
Keywords:
References:
Suggest new keywords:
Review article
renal cell carcinoma
urothelial (transitional cell) carcinoma
bladder cancer
end stage renal disease
dialysis
Reference attachment:
Suggest references:
Hickman LA, Sawinski D, Guzzo T, Locke JE. Urologic malignancies in kidney transplantation. Am J Transplant. 2018;18(1):13-22.
Note:
First review KL
OK to upload. MN; Please also make a clone with urothelial (transitional cell) carcinoma checked off under the harm to recipient section in place of renal cell carcinoma - Done, record n.1997 (EP)
Expert comments for publication:
In addition to discussing the frequency and risk factors involved, this article also contains detailed and useful discussions regarding screening and therapies for post-transplant renal cell and urothelial carcinomas. This comprehensive review covers both donor-transmitted and (mainly) de novo posttransplant cancers and also touches upon transplantation in the potential recipient with prior RCC.